Systemic Lupus Erythematosus News and Research

RSS

Systemic lupus erythematosus (SLE) is the form of the disease that most people are referring to when they say "lupus." The word "systemic" means the disease can affect many parts of the body. The symptoms of SLE may be mild or serious. Although SLE usually first affects people between the ages of 15 and 45 years, it can occur in childhood or later in life as well.

Patients with lupus nephritis ESRD choose hemodialysis as initial therapy

Newly published research shows that more patients with end-stage renal disease (ESRD) caused by lupus nephritis choose hemodialysis as their initial kidney replacement therapy over peritoneal dialysis and preemptive kidney transplantation.

7 Nov 2011

Vitamin D supplementation benefits people with lupus

The first study to report the effects vitamin D has on the immune system of people with lupus was reported this week a the American College of Rheumatology Annual Scientific Meeting in Chicago.

7 Nov 2011

HHS scientists to share recent rheumatology findings at 75th ACR annual meeting

Hospital for Special Surgery physician-scientists who focus on arthritis, lupus, vasculitis and related conditions are traveling from New York City to Chicago this week to share their recent findings at the 75th Annual Scientific Meeting of the American College of Rheumatology.

7 Nov 2011

IFNa-kinoid shows promise against lupus

The first study to show results using active immunotherapy against the signaling protein interferon alpha in the treatment of lupus will be presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.

7 Nov 2011

Study finds pregnancy safe for 80% of women with lupus

Promising research led by investigators at Hospital for Special Surgery may offer hope for women with lupus who once thought that pregnancy was too risky.

7 Nov 2011

Human Genome Sciences to present abstracts regarding BENLYSTA, SLE at ACR/ARHP meeting

Human Genome Sciences, Inc. announced today that several abstracts related to BENLYSTA (belimumab) and systemic lupus erythematosus will be presented at the annual meeting of the American College of Rheumatology/ Association of Rheumatology Health Professionals, being held in Chicago, IL from November 4 to November 9, 2011.

5 Nov 2011

Biogen Idec third quarter revenues increase 11% to $1.3 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its third quarter 2011 results.

28 Oct 2011

Biogen Idec enters global collaboration for oral Syk inhibitor program with Portola

Biogen Idec and Portola Pharmaceuticals, Inc. today announced that they have entered into an exclusive, worldwide collaboration and license agreement under which both companies will develop and commercialize highly selective, novel oral Syk inhibitors for the treatment of various autoimmune and inflammatory diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

28 Oct 2011

Study: Current lupus classification system is too detailed

The current classification system for kidney complications in patients with lupus is too detailed, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

28 Oct 2011

Xencor commences XmAb5871 Phase 1 trial in autoimmune diseases

Xencor, Inc., a company using its proprietary Protein Design Automation (PDA) platform technology to engineer next-generation antibodies, announced today the initiation of a Phase 1 clinical trial of XmAb5871, the company's therapeutic antibody for the treatment of autoimmune diseases.

22 Oct 2011

Women more likely to develop lupus at earlier ages

Debilitating. Destructive. Life-altering. These are just a few words used to describe autoimmune disease. Autoimmune diseases affect women 8 times more often than men, with lupus being one of the most disruptive. Lupus is a disease that occurs when a person's immune system attacks its own tissues and organs instead of attacking foreign invaders such as common viruses and bacteria. Lupus often results in wide-spread inflammation, pain, swelling and organ/tissue damage throughout the body.

19 Oct 2011

HealthWell Foundation introduces new lupus fund

The HealthWell Foundation, a nonprofit organization providing financial assistance to insured patients facing a variety of chronic and life-altering illnesses, announces the launch of a new fund supporting treatment for Systemic Lupus Erythematosus (SLE), the most common form of lupus.

22 Sep 2011

Adult stem cells hold hope for treatment of lupus

With a patient's own adult stem cells, there is new hope for the intractable autoimmune disease lupus - systemic lupus erythematosus (SLE) - which is difficult to cure.

17 Sep 2011

Biotica, Buck Institute collaborate to investigate polyketides in diseases of aging

The Buck Institute for Research on Aging and Biotica Technology Ltd. today announced a three-year collaboration to investigate polyketides in diseases of aging. Building on observations that rapamycin extends healthy lifespan in various species, the collaborators will evaluate rapamycin analogs and other polyketides in a broad range of age-related disease models to identify novel therapeutics.

14 Sep 2011

New report on the immunomodulators market outlook to 2016

TNF inhibitors indicated for the treatment of rheumatoid arthritis, psoriasis and inflammatory bowel disease formed the largest share of the market, according to a new report available on companiesandmarkets.com. The top three products: Remicade, Humira and Enbrel accounted for 40.1% of the market in 2010.

23 Aug 2011

Biotica acquires full rights to rapamycin analogue program from Pfizer

Biotica Technology Ltd. today announced that it has regained full rights from Pfizer Inc. to its rapamycin analogue program, including transfer of data and materials.

3 Aug 2011

Anthera reports increase in second quarter total operating expenses to $22.7 million

Anthera Pharmaceuticals, Inc., today announced financial results and business highlights for the quarter ended June 30, 2011.

29 Jul 2011

EC grants marketing authorization for BENLYSTA to treat SLE

GlaxoSmithKline and Human Genome Sciences, Inc. announced today that the European Commission has granted marketing authorization for BENLYSTA 10mg/kg as an add-on therapy in adult patients with active autoantibody-positive systemic lupus erythematosus, with a high degree of disease activity, despite standard therapy.

14 Jul 2011

Study reports high prevalence of vitamin D insufficiency in patients with psoriatic arthritis

New research reports a high prevalence of vitamin D insufficiency and deficiency among patients with psoriatic arthritis. Seasonal variation in vitamin D levels was not observed in patients in southern or northern locations.

11 Jul 2011

Positive results from etanercept pilot study against dermatomyositis

A multicenter pilot study of etanercept for treatment of dermatomyositis found no major safety concerns and many patients treated with the drug were successfully weaned from steroid therapy.

17 Jun 2011